FDA Approves Updated COVID-19 Vaccines from Pfizer, Moderna, Novavax for 2026-27 Season

The U.S. Food and Drug Administration (FDA) on Thursday approved updated COVID-19 vaccines from Moderna, Novavax-Sanofi, and the partnership of Pfizer and BioNTech for the 2026-27 immunization season, the companies confirmed.

New Shots Target Dominant XFG Variant

The regulatory green light follows a May recommendation from an FDA advisory panel, which voted 8-to-1 in favor of directing the next round of shots against the XFG variant. This decision marks a strategic shift from the 2025-26 season, when vaccines were formulated to target the LP.8.1 subvariant of the JN.1 strain.

All manufacturers had previously assured they could produce and supply the updated vaccines in time for the fall and winter immunization campaign. For investors, the approval solidifies the next cycle of potential revenue for the key pharmaceutical firms in the COVID-19 vaccine market.

Approved Vaccines and Market Context

Ad

The approval covers four distinct vaccine products, encompassing both mRNA and traditional protein-based technologies:

• Moderna: mNEXSPIKE and Spikevax (mRNA-based)
• Pfizer-BioNTech: Comirnaty (mRNA-based)
• Novavax-Sanofi: A protein-based vaccine

The Novavax-Sanofi shot utilizes a more conventional protein-based platform, which typically has a longer manufacturing lead time compared to the mRNA technology employed by its competitors. This approval ensures a variety of vaccine types will be available to the public.

Separately, the Centers for Disease Control and Prevention (CDC) has indicated that its COVID dashboard currently lacks new data on circulating strains. The agency attributed the gap to a low volume of sequencing submissions, highlighting a potential challenge in tracking the virus's evolution with precision.